DPD Testing Before Treatment With Fluoropyrimidines in the Amsterdam UMCs: An Evaluation of Current Pharmacogenetic Practice-Reference-Cited by-同舟云学术

DPD Testing Before Treatment With Fluoropyrimidines in the Amsterdam UMCs: An Evaluation of Current Pharmacogenetic Practice

Published:2020-01-28 Issue: Volume:10 Page:
ISSN:1663-9812
Container-title:Frontiers in Pharmacology
language:
Short-container-title:Front. Pharmacol.

Author:

Martens Forike K.,Huntjens Daan W.,Rigter Tessel,Bartels Meike,Bet Pierre M.,Cornel Martina C.

Publisher

Frontiers Media SA

Subject

Pharmacology (medical),Pharmacology

Reference16 articles.

1. Dihydropyrimidine dehydrogenase gene variation and severe 5-fluorouracil toxicity: a haplotype assessment;Amstutz;Pharmacogenomics,2009

2. Dihydropyrimidine dehydrogenase gene as a major predictor of severe 5-fluorouracil toxicity;Amstutz;Pharmacogenomics,2011

3. Safety, pharmacokinetics (PK), and cost-effectiveness of upfront genotyping of DPYD in fluoropyrimidine therapy;Deenen;J. Clin. Oncol.,2011

4. Prevention of severe toxicity from capecitabine, 5-fluorouracil and tegafur by screening for DPD-deficiency;Deenen;Ned. tijdschr. voor geneeskd.,2012

5. Upfront genotyping of DPYD*2A to individualize fluoropyrimidine therapy: A Safety and Cost Analysis;Deenen;J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol.,2016

Cited by 35 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Engagement of patients and the public in personalised prevention in Europe using genomic information: a scoping review;Frontiers in Public Health;2024-09-12

2. Implementation and Evaluation Strategies for Pharmacogenetic Testing in Hospital Settings: A Scoping Review;Therapeutic Drug Monitoring;2024-09-11

3. Capecitabine-induced severe adverse events—therapeutic drug monitoring andDPYD-gene analysis are recommended;BMJ Case Reports;2024-04

4. Practical Consensus Guidelines for the Use of S-1 in GI Malignancies;South Asian Journal of Cancer;2024-01

5. Implementation of pre‐emptive testing of a pharmacogenomic panel in clinical practice: Where do we stand?;British Journal of Clinical Pharmacology;2023-12-21